These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31928509)

  • 21. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis.
    Genre F; Armesto S; Corrales A; López-Mejías R; Remuzgo-Martínez S; Pina T; Ubilla B; Mijares V; Martín-Varillas JL; Rueda-Gotor J; Portilla V; Dierssen-Sotos T; González-López MA; González-Vela MDC; Blanco R; Llorca J; Hernández JL; González-Gay MÁ
    J Dermatolog Treat; 2017 Dec; 28(8):726-730. PubMed ID: 28489469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
    Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis.
    Wu JJ; Liu L; Asgari MM; Curtis JR; Harrold L; Salman C; Herrinton LJ
    J Eur Acad Dermatol Venereol; 2014 Oct; 28(10):1380-7. PubMed ID: 24708441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF inhibitors for psoriasis.
    Chima M; Lebwohl M
    Semin Cutan Med Surg; 2018 Sep; 37(3):134-142. PubMed ID: 30215629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis.
    Campanati A; Ganzetti G; Giuliodori K; Marra M; Bonfigli A; Testa R; Offidani A
    Int J Dermatol; 2015 Jul; 54(7):839-45. PubMed ID: 25877149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.
    Piaserico S; Osto E; Famoso G; Zanetti I; Gregori D; Poretto A; Iliceto S; Peserico A; Tona F
    Atherosclerosis; 2016 Aug; 251():25-30. PubMed ID: 27236353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents.
    Navarro R; Delgado-Jiménez Y; Guinea-Viniegra J; Llamas-Velasco M; Daudén E
    J Cutan Pathol; 2022 Feb; 49(2):116-122. PubMed ID: 34322902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic sarcoidosis reactions as a result of tumour necrosis factor-alpha treatment for patients with psoriasis.
    Bewley AP; Maleki S
    Clin Exp Dermatol; 2021 Dec; 46(8):1548-1550. PubMed ID: 34021925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
    van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
    Chiu HY; Hsueh PR; Tsai TF
    Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gestational lipid profile as an early marker of metabolic syndrome in later life: a population-based prospective cohort study.
    Adank MC; Benschop L; van Streun SP; Smak Gregoor AM; Mulder MT; Steegers EAP; Schalekamp-Timmermans S; Roeters van Lennep JE
    BMC Med; 2020 Dec; 18(1):394. PubMed ID: 33353543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of metabolic syndrome with pediatric psoriasis: a case-control study in Kabul, Afghanistan.
    Aalemi AK; Hamdard AG; Chen H
    Int J Dermatol; 2020 Apr; 59(4):451-456. PubMed ID: 32043572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
    Engin B; Tanakol A; Bulut H; Songür A; Vehid HE; Gökalp E; Kutlubay Z; Özkoca D; Tüzün Y; Serdaroğlu S
    Int J Dermatol; 2020 Feb; 59(2):207-215. PubMed ID: 31531981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapy.
    Varley CD; Deodhar AA; Ehst BD; Bakke A; Blauvelt A; Vega R; Yamashita S; Winthrop KL
    Rheumatology (Oxford); 2014 Feb; 53(2):332-7. PubMed ID: 24173434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study.
    Fernández-Armenteros JM; Gómez-Arbonés X; Buti-Soler M; Betriu-Bars A; Sanmartin-Novell V; Ortega-Bravo M; Martínez-Alonso M; Garí E; Portero-Otín M; Santamaria-Babi L; Casanova-Seuma JM
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):128-135. PubMed ID: 29953676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.